Stephen D. Gillies
Director Ejecutivo en Provenance Biopharmaceuticals Corp. .
Perfil
Stephen D.
Gillies is the founder of Provenance Biopharmaceuticals Corp.
founded in 2008, where he holds the position of President & Chief Executive Officer.
He is also the founder of Lexigen Pharmaceuticals Corp.
Dr. Gillies's current jobs include Director at Potentia Pharmaceuticals, Inc. and Senior Advisor at Delos Advisors Ltd.
Dr. Gillies's former jobs include Director at Galenea Corp., Director at Apellis Pharmaceuticals, Inc., Head-Pre Clinical Oncology Research at Merck KGaA, Vice President-Research at Damon Biotech, Inc., and Vice President-Research at Abbott Biotech, Inc. Dr. Gillies's education includes a graduate and doctorate degree from Rutgers State University of New Jersey and an undergraduate degree from the University of Massachusetts.
Cargos activos de Stephen D. Gillies
| Empresas | Cargo | Inicio |
|---|---|---|
Provenance Biopharmaceuticals Corp.
 Provenance Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Provenance Biopharmaceuticals Corp. engages in the research and development of immune therapeutics for the treatment of cancer. It offers immunocytokine technology, a drug that targets antibodies with immune-stimulating features of cytokines. The company was founded by Stephen D. Gillies and Jason M. Walsh in 2008 and is headquartered in Carlisle, MA. | Director Ejecutivo | 01/01/2008 |
Delos Advisors Ltd.
 Delos Advisors Ltd. Investment ManagersFinance Delos Advisors Ltd (Delos Capital) is a private equity and venture capital firm founded by Lin Zheng Chen in 2014. The firm is headquartered in Hong Kong. | Consultor / Asesor | - |
Antiguos cargos conocidos de Stephen D. Gillies.
| Empresas | Cargo | Fin |
|---|---|---|
| Damon Biotech, Inc. | Director Técnico/Científico/I+D | - |
| Abbott Biotech, Inc. | Director Técnico/Científico/I+D | - |
| APELLIS PHARMACEUTICALS, INC. | Director/Miembro de la Junta | - |
Galenea Corp.
 Galenea Corp. Pharmaceuticals: MajorHealth Technology Galenea Corp. is an emerging biotechnology company which engaged in the discovery of novel therapies for central nervous system (CNC) and respiratory diseases. The firm is focusing initially on utilizing proprietary technologies to generate calcineurin-related treatments for schizophrenia. It also offers synaptic transmission drug discovery platform for alzheimer’s disease (AD), parkinson’s disease, huntington’s disease, epilepsy, bipolar depression, schizophrenia, autism spectrum disorders, and traumatic brain injury. The company was founded Jianzhu chen, Susumu Tonegawa, Maria Karayiorgou, and David J. Gerber in 2004 and is headquartered in Wakefield, MA. | Director/Miembro de la Junta | - |
| MERCK KGAA | Corporate Officer/Principal | - |
Formación de Stephen D. Gillies.
| Rutgers State University of New Jersey | Doctorate Degree |
| University of Massachusetts | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| APELLIS PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 7 |
|---|---|
Potentia Pharmaceuticals, Inc.
 Potentia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Potentia Pharmaceuticals, Inc. operates as a biotechnology company. It focuses on the development of novel therapeutics and drug delivery technologies to address chronic inflammatory diseases. The company was founded by Cedric Francois, David Darst, Alec Machiels and Pascal Deschatelets in 2001 and is headquartered in Crestwood, KY. | Health Technology |
Galenea Corp.
Galenea Corp. Pharmaceuticals: MajorHealth Technology Galenea Corp. is an emerging biotechnology company which engaged in the discovery of novel therapies for central nervous system (CNC) and respiratory diseases. The firm is focusing initially on utilizing proprietary technologies to generate calcineurin-related treatments for schizophrenia. It also offers synaptic transmission drug discovery platform for alzheimer’s disease (AD), parkinson’s disease, huntington’s disease, epilepsy, bipolar depression, schizophrenia, autism spectrum disorders, and traumatic brain injury. The company was founded Jianzhu chen, Susumu Tonegawa, Maria Karayiorgou, and David J. Gerber in 2004 and is headquartered in Wakefield, MA. | Health Technology |
Provenance Biopharmaceuticals Corp.
Provenance Biopharmaceuticals Corp. Medical SpecialtiesHealth Technology Provenance Biopharmaceuticals Corp. engages in the research and development of immune therapeutics for the treatment of cancer. It offers immunocytokine technology, a drug that targets antibodies with immune-stimulating features of cytokines. The company was founded by Stephen D. Gillies and Jason M. Walsh in 2008 and is headquartered in Carlisle, MA. | Health Technology |
Lexigen Pharmaceuticals Corp.
 Lexigen Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Lexigen Pharmaceuticals Corp. focuses on commercial physical and biological research. The company was founded by Stephen D. Gillies and is headquartered in Billerica, MA. | Commercial Services |
| Damon Biotech, Inc. | Health Technology |
| Abbott Biotech, Inc. | |
Delos Advisors Ltd.
Delos Advisors Ltd. Investment ManagersFinance Delos Advisors Ltd (Delos Capital) is a private equity and venture capital firm founded by Lin Zheng Chen in 2014. The firm is headquartered in Hong Kong. | Finance |
- Bolsa de valores
- Insiders
- Stephen D. Gillies
